Ironwood Pharmaceuticals Strengthens Executive Leadership Team
– William Huyett Appointed to Chief Operating Officer –
– Gina Consylman Promoted to Senior Vice President, Chief Financial Officer –
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the
appointment of William Huyett as chief operating officer and the promotion of Gina Consylman to senior vice president and chief
financial officer.
“Strengthening our leadership team with these key appointments is critical for Ironwood as we seek to execute on our strategy to
deliver rapid top-line growth and advance our innovative mid- to late-stage product candidates,” said Peter Hecht, chief executive
officer at Ironwood. “Bill is a seasoned, strategic business partner who has a remarkable breadth of experience that will further
strengthen our ability to build a successful and innovative company. Gina has been an invaluable finance and enterprise leader at
Ironwood over the past three years and I am confident she will have an even greater impact in her expanded role. We are committed
to attracting and developing leaders with great strategic judgment, absolute integrity, and an owner-oriented mindset. Bill and
Gina exemplify these qualities and I am thrilled to have them as part of the executive team to drive our company forward.”
Mr. Huyett brings to Ironwood extensive experience in corporate strategy, capital allocation, finance, product
development/commercialization and corporate leadership in the life sciences industry and many other business sectors. At Ironwood,
he will be responsible for the company's finance, corporate strategy, corporate development, global operations, investor relations
and corporate communications functions. Mr. Huyett joins Ironwood following a distinguished 30-year career at McKinsey and Company,
Inc., where he served global clients in the life sciences, industrial and other technology-intensive sectors. Most recently,
he has been a senior partner emeritus at McKinsey. He was a leader in the firm’s pharmaceutical and medical products and its
strategy and corporate finance practices, and served on McKinsey’s Shareholder’s Council (its board of directors), serving as chair
of its Finance Committee. Prior to joining McKinsey, Mr. Huyett held a variety of line management positions with Allen-Bradley (now
Rockwell Automation, Inc.). Mr. Huyett serves on the board of directors of the London Stock Exchange-listed Georgia Healthcare
Group PLC. He also serves on several not-for-profit boards, including The Rockefeller University, the Marine Biological Laboratory,
the University of Virginia Darden School of Business and the YMCA of Greater Boston. He earned his B.S. in electronics engineering
and his M.B.A. from the University of Virginia.
Ms. Consylman is a 25-year veteran in the field of corporate finance. She joined Ironwood in 2014 and currently provides
oversight of the company’s finance, planning, accounting, tax, treasury and insurance functions. Prior to joining Ironwood, she was
vice president, corporate controller and principal accounting officer at Analogic Corporation, served as senior director, corporate
accounting at Biogen Inc., and as corporate controller at Varian Semiconductor Equipment Associates, Inc. A Certified Public
Accountant, Ms. Consylman began her career in public accounting at Ernst & Young LLP. She holds a B.S. in accounting from
Johnson & Wales University and a M.S. in taxation from Bentley University.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ:IRWD) is a commercial biotechnology company focused on creating medicines that make a
difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two
innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome
with constipation (IBS‐C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved for the treatment of
hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically
appropriate daily dose of a xanthine oxidase inhibitor (XOI) alone. We are also advancing a pipeline of innovative product
candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease, diabetic nephropathy, heart
failure with preserved ejection fraction, achalasia and sickle cell disease. Ironwood was founded in 1998 and is headquartered in
Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both
these locations.
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these
forward-looking statements, including statements about Ironwood’s leadership team, the strength and value thereof, and the
leadership team’s impact on the company and its business, growth, business strategy, pipeline advancement, productivity and the
potential of its products and product candidates and their impact, as well as statements about the timing of any of the
foregoing. Each forward‐looking statement is subject to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to
management and executive appointments; our ability to effectively advance our strategy; the effectiveness of development and
commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development;
the risk that findings from our completed nonclinical and clinical studies may not be replicated in later studies; efficacy, safety
and tolerability of linaclotide, lesinurad and our product candidates; decisions by regulatory authorities; the risk that we are
unable to successfully integrate lesinurad into our existing business, commercialize lesinurad or realize the anticipated benefits
of the lesinurad transaction; the risk that we may never get sufficient patent protection for our products and our product
candidates or that we are not able to successfully protect such patents; the outcomes in legal proceedings to protect or enforce
the patents relating to our products and product candidates, including ANDA litigation; developments in the intellectual property
landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have
the anticipated effect on our company revenues, linaclotide, lesinurad or our product candidates; the risk that we are unable to
manage our operating expenses or cash use for operations, or are unable to commercialize our products, within the guided ranges or
otherwise as expected and those risks listed under the heading "Risk Factors" and elsewhere in Ironwood's Quarterly Report on Form
10-Q for the quarter ended September 30, 2017, and in our subsequent SEC filings. These forward-looking statements
(except as otherwise noted) speak only as of the date of this press release, and Ironwood undertakes no obligation to update these
forward-looking statements.
Investor and Media Relations
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
Senior Director, Investor Relations and Corporate Communications
mkaya@ironwoodpharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20171128005464/en/